Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025

Rhea-AI Summary

Xenon (Nasdaq: XENE) will host an investor webinar on December 10, 2025, 10:00 AM ET to review data presented at the American Epilepsy Society Annual Meeting (AES 2025).

The webinar covers new long-term results from the ongoing X-TOLE open-label extension of azetukalner in focal onset seizures, real-world data on depression and titration burden in epilepsy, and an update on preparations for commercialization of azetukalner. A live webcast and replay will be available on the company Investors site.

News Market Reaction

+3.29%

1 alert

+3.29% News Effect

On the day this news was published, XENE gained 3.29%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Investor webinar date: December 10, 2025 Webinar time: 10:00–11:00 AM Eastern Time Net loss: $90.9 million +5 more

8 metrics

Investor webinar date December 10, 2025 Azetukalner and epilepsy data update: AES 2025 webinar

Webinar time 10:00–11:00 AM Eastern Time Investor webinar duration

Net loss $90.9 million Q3 2025 net loss from 10-Q

Loss per share $1.15 Q3 2025 basic and diluted loss per share

R&D expense $77.1 million Q3 2025 research and development expense

G&A expense $19.3 million Q3 2025 general and administrative expense

Cash & securities $555.3 million Cash, cash equivalents and marketable securities as of Sept 30, 2025

Net cash used in ops $197.6 million Net cash used in operations, first nine months 2025

Market Reality Check

Price: $41.76 Vol: Volume 856,352 vs 20-day ...

normal vol

$41.76 Last Close

Volume Volume 856,352 vs 20-day average 805,233 shows trading close to typical levels. normal

Technical Shares at $43.66, trading above the 200-day MA of $36.01 and between the 52-week high $46.60 and low $26.74.

Peers on Argus

Peers showed mixed moves: IMVT up 5.75%, SRRK up 3.86%, while SLNO fell 7.19% an...

Peers showed mixed moves: IMVT up 5.75%, SRRK up 3.86%, while SLNO fell 7.19% and RARE was down 0.6%, indicating stock-specific factors rather than a uniform sector trend.

Historical Context

5 past events · Latest: Dec 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 05	Epilepsy data update	Positive	+0.7%	Long-term 48‑month azetukalner OLE data with durable seizure reductions.
Dec 04	Equity inducement grants	Neutral	+0.7%	Stock option grants to new employees under inducement equity plan.
Dec 03	Investor webinar announcement	Positive	+3.3%	Planned webinar to review AES 2025 epilepsy data and commercialization plans.
Nov 25	Conference data preview	Positive	+4.5%	Plan for seven AES 2025 posters with long-term and preclinical epilepsy data.
Nov 06	Investor conferences	Positive	-0.9%	Participation in November healthcare investor conferences featuring azetukalner.

Pattern Detected

Recent Xenon news, particularly around azetukalner and AES 2025 data, has generally been followed by modest positive share reactions, with one small divergence on an investor conference update.

Recent Company History

This announcement adds to a series of communications highlighting Xenon’s lead asset azetukalner and broader pipeline. In late November and December 2025, the company flagged new azetukalner open-label extension data and AES 2025 poster plans, followed by detailed 48‑month efficacy results showing durable seizure reductions. Corporate updates included inducement equity grants and participation in investor conferences. Collectively, these events emphasize ongoing late-stage epilepsy development and commercialization preparation, which the current investor webinar is designed to further explain.

Market Pulse Summary

This announcement highlights an investor webinar on December 10, 2025 to review new long-term azetuk...

Analysis

This announcement highlights an investor webinar on December 10, 2025 to review new long-term azetukalner data from the X‑TOLE open-label extension in focal onset seizures and real‑world epilepsy findings, alongside commercialization planning. Recent history shows multiple AES 2025‑related updates and advancing Phase 3 programs. At the same time, Q3 2025 featured a net loss of $90.9 million, underscoring the importance of monitoring cash levels, pivotal trial readouts, and execution on commercialization milestones.

Key Terms

open-label extension, focal onset seizures, Phase 3, Kv7, +1 more

5 terms

open-label extension medical

"new long-term data from the ongoing X-TOLE open-label extension study of azetukalner"

An open-label extension is a continuation of a clinical trial where all participants and researchers know which treatment is being given, often after an initial blinded phase. It allows further study of a drug's long-term safety and effectiveness. For investors, it can indicate ongoing interest and confidence in a product's potential, influencing perceptions of its future value.

focal onset seizures medical

"open-label extension study of azetukalner in focal onset seizures (FOS)"

Focal onset seizures are seizures that begin in a specific part of the brain and can cause localized symptoms such as brief changes in awareness, unusual sensations, or jerking in one limb; they can sometimes spread to affect the whole brain. Investors care because these seizures define patient groups, influence how drugs and devices are tested and approved, and shape market size, pricing and risk — like a localized outage that requires a targeted fix rather than a whole-system replacement.

Phase 3 medical

"azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

Kv7 medical

"novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials"

Kv7 denotes a family of potassium ion channels in cell membranes that act like tiny gatekeepers controlling electrical signals in nerves and muscles; drugs that open or block these channels can change how cells fire. Investors care because Kv7 is a common drug target for conditions such as epilepsy, pain and some cardiac disorders, so breakthroughs or setbacks in Kv7-focused therapies can affect clinical progress, regulatory reviews and potential market value.

Nav1.7 medical

"including Kv7 and Nav1.7 programs in Phase 1 development for the potential treatment of pain"

NAV1.7 is a specific protein in nerve cells that helps transmit pain signals to the brain; think of it as a gatekeeper that opens and closes to let electrical messages through. Investors watch drugs that block or modify NAV1.7 because successful therapies could relieve chronic pain without opioids, creating large market opportunities, while clinical setbacks or safety issues can sharply affect a company's valuation.

AI-generated analysis. Not financial advice.

VANCOUVER, British Columbia and BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will host an investor webinar focused on its data presentations at the American Epilepsy Society Annual Meeting (AES 2025), including new long-term data from the ongoing X-TOLE open-label extension study of azetukalner in focal onset seizures (FOS) and real world study data on the impact of depression and burden of titration in epilepsy. The webinar will also include an update on the company’s progress preparing for commercialization of azetukalner.

Webinar	Azetukalner and Epilepsy Data Update: AES 2025
Date	Wednesday, December 10, 2025
Time	10:00-11:00 AM Eastern Time
Webcast Registration	Register here (link)
Format	Questions may be submitted via chat function during the live webinar or submitted in advance via email to investors@xenon-pharma.com.

More information on Xenon’s AES 2025 presentations can be found here. A live webcast of the webinar will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed date and time are subject to change.

About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD), and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including Kv7 and Nav1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.

Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements are not based on historical fact, and include statements regarding the timing of and potential results from clinical studies; the potential efficacy, safety profile, future development plans in current and anticipated indications, addressable market, regulatory success and commercial potential of our and our partners’ product candidates; the efficacy of our clinical study designs; our ability to successfully develop and achieve milestones in our azetukalner and other pipeline and development programs, including the anticipated filing of INDs and NDAs; the timing and results of our interactions with regulators; our ability to successfully develop and obtain regulatory approval of azetukalner and our other product candidates; and anticipated timing of topline data readout from our clinical studies of azetukalner. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: clinical studies may not demonstrate safety and efficacy of any of our or our collaborators’ product candidates; promising results from pre-clinical development activities or early clinical study results may not be replicated in later clinical studies; our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations may be incorrect; our ongoing discovery and pre-clinical efforts may not yield additional product candidates; any of our or our collaborators’ product candidates, including azetukalner, may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; regulatory agencies may impose additional requirements or delay the initiation or completion of clinical studies; the impact of market, industry, and regulatory conditions on clinical study enrollment; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; the impact of unstable economic conditions in the general domestic and global economic markets; adverse conditions from geopolitical events; as well as the other risks identified in our filings with the U.S. Securities and Exchange Commission and the securities commissions in British Columbia, Alberta, and Ontario. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.

Contact:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
Media: media@xenon-pharma.com
Investors: investors@xenon-pharma.com

FAQ

When is the Xenon (XENE) investor webinar on AES 2025 data?

The webinar is scheduled for Wednesday, December 10, 2025 at 10:00 AM ET.

What key azetukalner data will Xenon (XENE) discuss on December 10, 2025?

Xenon will review new long-term data from the ongoing X-TOLE open-label extension in focal onset seizures.

Will Xenon (XENE) present real-world epilepsy findings during the webinar?

Yes; the webinar includes real-world study data on the impact of depression and the burden of titration in epilepsy.

How can investors access the Xenon (XENE) webinar and replay?

A live webcast will be available via the company Investors website and a replay will be posted after the event.

Will the Xenon (XENE) webinar include a commercialization update for azetukalner?

Yes; the company will provide an update on progress preparing for commercialization of azetukalner.

How can investors submit questions for the Xenon (XENE) December 10, 2025 webinar?

Questions may be submitted via the webinar chat during the live event or emailed in advance to investors@xenon-pharma.com.